GHRP-2

A potent hexapeptide growth hormone secretagogue that stimulates GH release through the ghrelin receptor, with secondary effects on cortisol and prolactin.

Also known as: Pralmorelin, KP-102, Growth Hormone Releasing Peptide-2

Regulatory Status

Currently Restricted

Classification date: 2024-06-01

Compounding: Not currently available for compounding

Evidence Summary

Moderate15 human studies published

Key Studies

Growth hormone releasing peptide-2 (GHRP-2): GH, cortisol, and prolactin response in humans
Diagnostic reliability of GHRP-2 testing for adult GH deficiency
Long-term treatment with GHRP-2 in elderly subjects: effects on GH, IGF-1, and body composition

How It Works

GHRP-2 is a synthetic hexapeptide that binds to the growth hormone secretagogue receptor (GHSR/ghrelin receptor) on pituitary somatotrophs, triggering robust GH release. It is more potent than GHRP-6 but less selective than ipamorelin, as it also elevates cortisol, prolactin, and ACTH at higher doses. It stimulates appetite through ghrelin receptor activation and produces GH release that is additive when combined with GHRH analogs. It is approved in Japan as a diagnostic agent for GH deficiency (under the name pralmorelin).

Common Applications

Growth hormone deficiency diagnosis (approved in Japan)GH optimization and body compositionAppetite stimulation in wasting conditionsRecovery and healing support

Safety & Considerations

Side effects include increased appetite, water retention, cortisol elevation, and mild prolactin increases at higher doses. Repeated use may cause desensitization. Less selective than ipamorelin, making it less ideal for long-term use. Should not be used in patients with pituitary tumors or active malignancies. Currently not legal for compounding in the US.

Regulatory classifications can change rapidly. The information shown here was last verified on 2024-06-01. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.